Results 141 to 150 of about 38,108 (242)
Temozolomide treatment activates GSK3β, driving DNMT1 phosphorylation, destabilization, and CD47 promoter hypomethylation in glioblastoma. This epigenetic shift upregulates CD47, enabling TMZ‐treated GBM cells to evade macrophage phagocytosis, survive chemotherapy, and acquire resistance.
Jie Li +11 more
wiley +1 more source
A new class of lysosome‐directed molecular glue degraders selectively enhance CAPRIN1–APP interactions, driving APP degradation and reducing amyloid‐β production in human neurons and Alzheimer's disease mouse models. This CAPRIN1‐dependent targeted protein degradation strategy reveals a previously unrecognized therapeutic approach for disrupting the ...
Sunghan Jung +15 more
wiley +1 more source
This study systematically compares small extracellular vesicles (sEVs) derived from four neural cell lines, revealing how cellular origin shapes vesicle biophysical properties and proteomic cargo. Distinct, lineage‐specific signatures linked to neuronal, astrocytic, and microglial functions are identified, highlighting the importance of cell source ...
Muhammad Waqas Salim +4 more
wiley +1 more source
Neurological manifestations of lysosomal storage diseases. [PDF]
Elendu C +15 more
europepmc +1 more source
Advancing the Research and Development of Enzyme Replacement Therapies for Lysosomal Storage Diseases. [PDF]
Puhl AC, Ekins S.
europepmc +1 more source
Lysosomal Storage Diseases—Regulating Neurodegeneration
Rob U. Onyenwoke, Jay E. Brenman
doaj
Feasibility and efficacy of the forced oscillation technique in patients with lysosomal storage diseases. [PDF]
Alblooshi A +3 more
europepmc +1 more source
Secondary Mitochondrial Dysfunction as a Cause of Neurodegenerative Dysfunction in Lysosomal Storage Diseases and an Overview of Potential Therapies. [PDF]
Stepien KM +5 more
europepmc +1 more source
Extracellular Vesicles as Tools for Crossing the Blood-Brain Barrier to Treat Lysosomal Storage Diseases. [PDF]
Lerussi G +6 more
europepmc +1 more source
Objective Rheumatoid arthritis (RA) often involves extra‐articular complications, including interstitial lung disease (ILD) and/or pulmonary nodules. Transcriptomic profiling of lung tissue provides the opportunity to directly assess cell‐specific gene expression and corresponding pathway activation in different types of rheumatoid lung disease ...
Tracy Tabib +8 more
wiley +1 more source

